Multiple Myeloma – Geographic Focus: China – Multiple Myeloma | China In-Depth | China
MARKET OUTLOOK
Multiple myeloma is an incurable hematological malignancy with a 100% mortality rate that affects a sizeable Chinese population every year. With the introduction of proteasome inhibitors and immunomodulatory agents in China, the median overall survival has seen much improvement in the last decade. The multiple myeloma market of China is expected to expand further over the 2018-2028 period, fueled by the increasing disease incidence and an increasing uptake of targeted agents; most notably that of the recently launched daratumumab and upcoming pomalidomide, due to their potential efficacy in improving PFS in patients, especially in the relapsed/refractory setting. Despite the availability of a number of traditional and novel agents, there will remain a high unmet need for therapies that can significantly improve patients’ PFS and OS, representing an opportunity for new drug developers. Additionally, with the ongoing reforms in the regulatory and access & reimbursement landscape of China, multinational companies are likely to be increasingly incentivized to enter the multiple myeloma market.
QUESTIONS ANSWERED
- How large is China’s drug-treatable multiple myeloma population, and how will drug-treatment rate change during the forecast period?
- Which are the most commercially relevant drugs in China’s multiple myeloma market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the key market access considerations for key therapies in the multiple myeloma pipeline in China? What sales/uptake could they secure in multiple myeloma? What are interviewed experts’ opinions on the key emerging therapies?
- What are the key drivers and constraints in the Chinese multiple myeloma market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Release date
December 2019
Geographies
China
Primary Research
Qualitative and quantitative insights driven by 5 country-specific interviews with thought-leading hematologist oncologists. Supported by survey data collected for this and other DRG research.
EPIDEMIOLOGY
Diagnosed incidence of multiple myeloma by disease stage, line of therapy, and geography (urban and rural). Clinically and market relevant drug-treatable populations.
FORECAST
Ten-year, annualized, drug-level sales and patient shares of key multiple myeloma therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase III/PR: 9 regimens; Phase II: 4 agents; coverage of select early-phase products.
Table of contents
- Multiple Myeloma - Geographic Focus: China - Multiple Myeloma | China In-Depth | China
- China In-Depth Multiple Myeloma
Karan Verma, M.Sc., is a principal analyst on the China In-Depth team at Clarivate. He is involved in primary and secondary market research to create syndicated landscape and forecast content and provide Chinese market-specific insights in various therapy areas, including CAR T-cell therapies, prostate cancer, hepatocellular carcinoma, multiple myeloma, non-Hodgkin’s lymphoma, migraine, type 2 diabetes, and multiple sclerosis. He has expertise in market forecasting, competitive intelligence, benchmarking, and brand performance analytics. He obtained his M.Sc. in biomedical engineering from the University of Warwick in Coventry, United Kingdom, and a B.E. in biomedical engineering from Maharshi Dayanand University in Haryana, India.
Akash Saini, M.Sc., Ph.D., is the manager of the China In-Depth team at Clarivate. In this role, he leads the efforts to create syndicated landscape and forecast content on various therapy areas for the Chinese market. Previously, he was an assistant manager at BioXcel, where he led consulting projects based on in-silico drug discovery and identification of drug repurposing and in-licensing opportunities. Dr. Saini received his Ph.D. in biochemistry and biotechnology from the International Centre for Genetic Engineering and Biotechnology in New Delhi and conducted postdoctoral research at the University of Massachusetts Medical School. He earned his M.Sc. in biotechnology from Jawaharlal Nehru University in India.
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.